Insider Screener
Real-time Form 4 Filtering Engine
| Filing Date | Trade Date | Ticker | Company Name | Reporting Person | Relationship | Industry (by SEC) | Type | Price | Qty | Total, $ | Owned After | Change, % |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-03-09 00:26 | 2023-03-06 | ARQT | Arcutis Biotherapeutics Inc. | OSBORNE DAVID W | Officer; Chief Technical Officer | Pharmaceutical Preparations | SALE | $15.26 | 690 | $10,532 | 268,854 | -0.3% |
| 2023-03-03 03:03 | 2023-02-28 | ARQT | Arcutis Biotherapeutics Inc. | OSBORNE DAVID W | Officer; Chief Technical Officer | Pharmaceutical Preparations | SALE | $15.96 | 2,005 | $32,002 | 254,644 | -0.8% |
| 2022-07-13 02:30 | 2022-07-08 | ARQT | Arcutis Biotherapeutics Inc. | OSBORNE DAVID W | Officer; Chief Technical Officer | Pharmaceutical Preparations | SALE | $25.41 | 2,197 | $55,835 | 256,649 | -0.8% |
| 2022-04-22 01:32 | 2022-04-21 | ARQT | Arcutis Biotherapeutics Inc. | OSBORNE DAVID W | Officer; Chief Technical Officer | Pharmaceutical Preparations | SALE | $20.42 | 2,197 | $44,872 | 257,229 | -0.8% |
| 2022-03-08 04:47 | 2022-03-04 | ARQT | Arcutis Biotherapeutics Inc. | OSBORNE DAVID W | Officer; Chief Technical Officer | Pharmaceutical Preparations | SALE | $16.85 | 856 | $14,420 | 259,426 | -0.3% |
| 2022-03-04 00:18 | 2022-03-01 | ARQT | Arcutis Biotherapeutics Inc. | OSBORNE DAVID W | Officer; Chief Technical Officer | Pharmaceutical Preparations | SALE | $17.75 | 775 | $13,758 | 246,982 | -0.3% |
| 2021-03-04 00:50 | 2021-03-01 | ARQT | Arcutis Biotherapeutics Inc. | OSBORNE DAVID W | Officer; Chief Technical Officer | Pharmaceutical Preparations | SALE | $34.57 | 780 | $26,968 | 237,253 | -0.3% |
| 2020-12-16 23:15 | 2020-12-14 | ARQT | Arcutis Biotherapeutics Inc. | OSBORNE DAVID W | Officer; Chief Technical Officer | Pharmaceutical Preparations | SALE | $30.00 | 15,000 | $450,000 | 250,533 | -5.6% |
| 2020-10-02 04:01 | 2020-09-29 | ARQT | Arcutis Biotherapeutics Inc. | OSBORNE DAVID W | Officer; Chief Technical Officer | Pharmaceutical Preparations | SALE | $30.00 | 15,000 | $450,000 | 264,279 | -5.4% |
| 2003-08-14 02:16 | 2003-08-11 | ATRX | N/A | OSBORNE DAVID W | Officer; Vice President - Dermatology | Other | OPT+S | $24.31 | 6,000 | $145,860 | 5,647 | -51.5% |
| 2003-08-08 20:24 | 2003-08-07 | ATRX | N/A | OSBORNE DAVID W | Officer; VP Dermatology | Other | OPT+S | $23.92 | 20,000 | $478,350 | 5,647 | -78.0% |
| 2003-08-08 03:29 | 2003-08-05 | ATRX | N/A | OSBORNE DAVID W | Officer; VP Dermatology | Other | OPT+S | $24.16 | 6,500 | $157,034 | 108,000 | -5.7% |
| 2003-08-08 03:55 | 2003-08-05 | ATRX | N/A | OSBORNE DAVID W | Officer; VP Dermatology | Other | OPT+S | $24.16 | 6,500 | $157,034 | 5,647 | -53.5% |
Strategic Signal Filtering
Our screener allows you to cut through the noise of routine stock grants and small trades. By focusing on high-value transactions from C-suite executives (CEO/CFO), you can identify where the "Smart Money" is being deployed with maximum conviction.
Investing Without Illusions
Insider data is not a magic wand, but it is the most honest indicator available. While insiders sell for many reasons (taxes, personal needs), they generally buy for only one: they believe the stock price is undervalued. We provide the tools to track these skin-in-the-game moves.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.